MX2024012608A - Optimizacion de la plataforma de suspension hek293 para mejorar los titulos de raav - Google Patents

Optimizacion de la plataforma de suspension hek293 para mejorar los titulos de raav

Info

Publication number
MX2024012608A
MX2024012608A MX2024012608A MX2024012608A MX2024012608A MX 2024012608 A MX2024012608 A MX 2024012608A MX 2024012608 A MX2024012608 A MX 2024012608A MX 2024012608 A MX2024012608 A MX 2024012608A MX 2024012608 A MX2024012608 A MX 2024012608A
Authority
MX
Mexico
Prior art keywords
optimization
suspension platform
improved raav
hek293 suspension
raav titers
Prior art date
Application number
MX2024012608A
Other languages
English (en)
Spanish (es)
Inventor
Ali Aghajanirefah
Original Assignee
Adverum Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverum Biotechnologies Inc filed Critical Adverum Biotechnologies Inc
Publication of MX2024012608A publication Critical patent/MX2024012608A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024012608A 2022-04-11 2024-10-10 Optimizacion de la plataforma de suspension hek293 para mejorar los titulos de raav MX2024012608A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263329856P 2022-04-11 2022-04-11
US202263331438P 2022-04-15 2022-04-15
PCT/US2023/017838 WO2023200679A1 (en) 2022-04-11 2023-04-07 OPTIMIZATION OF HEK293 SUSPENSION PLATFORM FOR IMPROVED rAAV TITERS

Publications (1)

Publication Number Publication Date
MX2024012608A true MX2024012608A (es) 2024-11-08

Family

ID=88330208

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012608A MX2024012608A (es) 2022-04-11 2024-10-10 Optimizacion de la plataforma de suspension hek293 para mejorar los titulos de raav

Country Status (9)

Country Link
US (1) US20250250547A1 (cg-RX-API-DMAC7.html)
EP (1) EP4508198A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025512382A (cg-RX-API-DMAC7.html)
KR (1) KR20250004745A (cg-RX-API-DMAC7.html)
CN (1) CN119053692A (cg-RX-API-DMAC7.html)
AU (1) AU2023254746A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245930A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024012608A (cg-RX-API-DMAC7.html)
WO (1) WO2023200679A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12662271B2 (en) 2024-02-13 2026-06-23 Culture Biosciences, Inc. Apparatus, system, and method for automated filling of syringes
EP4683041A1 (en) 2024-02-29 2026-01-21 LG Energy Solution, Ltd. Method for regenerating cathode active material, and regenerated cathode active material prepared thereby
WO2026013235A1 (en) * 2024-07-11 2026-01-15 Ferring International Center S.A. Methods of producing recombinant adenovirus vectors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208315B2 (en) * 2000-01-05 2007-04-24 Fred Hutchinson Cancer Research Center Compositions and methods for efficient AAV vector production
WO2013076309A1 (en) * 2011-11-24 2013-05-30 Genethon Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
EP3927723A1 (en) * 2019-02-22 2021-12-29 Life Technologies Corporation Suspension system for adeno associated virus production

Also Published As

Publication number Publication date
JP2025512382A (ja) 2025-04-17
EP4508198A1 (en) 2025-02-19
US20250250547A1 (en) 2025-08-07
WO2023200679A1 (en) 2023-10-19
CA3245930A1 (en) 2023-10-19
EP4508198A4 (en) 2026-04-22
AU2023254746A1 (en) 2024-10-10
CN119053692A (zh) 2024-11-29
KR20250004745A (ko) 2025-01-08

Similar Documents

Publication Publication Date Title
BR112012011529A2 (pt) sistema de laser, e, método para escanear um feixe de laser
WO2020198509A3 (en) Modified oligonucleotides with increased stability
Herdy et al. The RNA‐binding protein HuR/ELAVL1 regulates IFN‐β mRNA abundance and the type I IFN response
BR112021022666A2 (pt) Frações de separação e seus métodos e uso
BR112018076281A2 (pt) imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
MX2020010871A (es) Compuestos de 5'-caperuza-trinucleótidos u oligonucleótidos superiores y sus usos en estabilizar arn, que expresan proteínas y en la terapia.
PL439808A1 (pl) Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał
BR112017013599A2 (pt) composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras.
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
CY1113409T1 (el) Αναστολεις ακτ και ρ70 s6 κινασης
BR112022018254A2 (pt) Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo
BR112022015325A2 (pt) Sistemas e métodos para alta produção de microganismos recombinantes e uso dos mesmos
BR112022015601A2 (pt) Grandes vetores genéticos e dispensação e usos dos mesmos
WO2024227174A3 (en) Antibodies that bind ox40l and methods of use
BR112022001336A8 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
BR112022001329A2 (pt) Anticorpo biespecífico anti-egfr/anti-4-1bb e uso do mesmo
EA202192923A1 (ru) Антитела и способы лечения инфекции, вызываемой вирусом гриппа а
JOP20250152A1 (ar) الفيروس المحلل للورم واستخداماته
PH12020551642A1 (en) Aav compositions, methods of making and methods of use
BR112018010669A2 (pt) anticorpo anti-pcsk9 e utilização do mesmo
JOP20190179A1 (ar) نوكليوتيدات ثنائية حلقية كناهضات لـ sting
CL2025001926A1 (es) Anticuerpo anti-tgfß3; anticuerpo anti-tgfß2/3; anticuerpo anti-tgfß2; método de producción; y su uso.
BR112022024996A2 (pt) Anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, agente terapêutico, uso do anticorpo e método para tratar um indivíduo com hepatite b
Ziehr et al. Human cytomegalovirus TRS1 protein associates with the 7‐methylguanosine mRNA cap and facilitates translation
EA202192893A1 (ru) Среда для культивирования эукариотических клеток